— Know what they know.
Not Investment Advice
Also trades as: 600196.SS (SHH) · $vol 96M · 2196.HK (HKSE) · $vol 9M

SFOSF OTC

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
1W: +11.4% 1M: +11.4% 3M: +21.3% YTD: -11.9% 1Y: -30.0% 3Y: +10.9% 5Y: -51.0%
$2.45
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Buy · Power 72 · $6.5B mcap · 941M float · 0.0000% daily turnover · Short 57% of daily vol

Cash Flow Trends

Operating Cash Flow
$4.5B +31.1% ▲
5Y CAGR: +6.8%
Capital Expenditures
$4.4B +17.4% ▲
5Y CAGR: +2.2%
Free Cash Flow
$67M +103.5% ▲
Dividends Paid
$2.1B +16.1% ▲
Buybacks
$238M +0.0% ▲
Net Change in Cash
-$111M +93.3% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2020FY2021FY2022FY2023FY2024
— Operating Activities —
Net Income$3.9B$5.0B$3.9B$2.4B$3.5B
Depreciation & Amort.$1.7B$1.8B$2.3B$3.1B$3.0B
Stock-Based Comp.$55M$64M$54M$36M$21M
Change in Working Capital-$1.4B$260M-$1.4B-$937M-$1.4B
Other Non-Cash Items$925M$841M-$544M-$241M-$707M
Operating Cash Flow$2.6B$3.9B$4.2B$4.4B$4.5B
— Investing Activities —
Capital Expenditures-$4.4B-$5.0B-$5.9B-$5.3B-$4.4B
Acquisitions (Net)-$140M$381M-$488M-$924M-$84M
Investment Purchases-$1.1B-$1.4B-$1.5B-$943M-$846M
Investment Sales$2.0B$2.2B$4.6B$2.7B$1.5B
Other Investing-$1.1B-$9M-$836M-$302M$229M
Investing Cash Flow-$4.7B-$3.9B-$4.1B-$4.8B-$3.6B
— Financing Activities —
Net Debt Issuance$2.3B$1.8B$3.7B$1.7B$410M
Stock Repurchased$0$0$0$0-$238M
Dividends Paid-$1.0B-$1.1B-$1.4B-$2.5B-$2.1B
Other Financing$1.0B-$716M$4.6B-$596M$885M
Financing Cash Flow$1.5B-$831M$4.4B-$1.3B-$1.0B
Net Change in Cash-$959M-$874M$4.7B-$1.7B-$111M
Cash End of Period$7.3B$6.5B$11.2B$9.5B$9.4B
Free Cash Flow-$1.9B-$1.0B-$1.7B-$1.9B$67M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms